Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...

Sumitomo Mitsui Trust Group Inc. lowered its stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a report issued on Wednesday, MarketBeat reports. Separately ...

Nano-X Imaging is a disruptive biotech investment. The AI push in the health sector is a long-term tailwind. See why we rate ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...